Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
暂无分享,去创建一个
Armando Santoro | David Khayat | David Cunningham | E. Van Cutsem | A. Santoro | D. Khayat | C. Verslype | Y. Humblet | D. Cunningham | S. Siena | I. Chau | A. Harstrick | Eric Van Cutsem | Salvatore Siena | Ian Chau | Yves Humblet | Harry Bleiberg | Danny Bets | Matthias Mueser | Andreas Harstrick | Chris Verslype | H. Bleiberg | D. Bets | M. Mueser
[1] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[2] M. Mandal,et al. Physical Interaction between Epidermal Growth Factor Receptor and DNA-dependent Protein Kinase in Mammalian Cells* , 1998, The Journal of Biological Chemistry.
[3] F. Russo,et al. EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma. , 1998, Acta oncologica.
[4] L. Norton,et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[6] L. Saltz,et al. The presence and intensity of the cetuximab- induced acne-like rash predicts increased survival in studies across multiple malignances , 2003 .
[7] N. Normanno,et al. Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.
[8] Neal J Meropol,et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Douglas B. Evans,et al. Restoring apoptosis in pancreatic cancer cells by targeting the nuclear factor-κb signaling pathway with the anti-epidermal growth factor antibody IMC-C225 , 2003, Journal of Gastrointestinal Surgery.
[10] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[11] N. Goldstein,et al. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma , 2001, Cancer.
[12] Daniel J Sargent,et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] N. Saijo,et al. Antitumor activity of the selective epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) Iressa® (ZD1839) in an EGFR‐expressing multidrug‐resistant cell line in vitro and in vivo , 2002, International journal of cancer.
[14] M Van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.
[15] Lee M Ellis,et al. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[16] A. Harłozińska,et al. Expression of the Tyrosine Kinase Activity Growth Factor Receptors (EGFR, ERB B2, ERB B3) in Colorectal Adenocarcinomas and Adenomas , 2000, Tumor Biology.
[17] G. Tortora,et al. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[18] F. Russo,et al. EGF, TGF-a, and EGF-R in Human Colorectal Adenocarcinoma , 1998 .
[19] G. Tortora,et al. Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. , 2003, European journal of cancer.
[20] Christian Jacques,et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer , 1998, The Lancet.
[21] P. Harari,et al. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[22] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[23] M. Villalona-Calero,et al. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] K. Ono,et al. ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. , 1999, Molecular pharmacology.
[25] A. Miller,et al. Reporting results of cancer treatment , 1981, Cancer.
[26] Masahiro Fukuoka,et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] Y. Sugiyama,et al. Active efflux of CPT-11 and its metabolites in human KB-derived cell lines. , 1999, The Journal of pharmacology and experimental therapeutics.
[28] Y. Yarden,et al. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. , 2000, Advances in cancer research.
[29] C. Wilson,et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] David Cella,et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. , 2003, JAMA.
[31] F. Lévi,et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] L. Saltz,et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. , 2000, The New England journal of medicine.
[33] H. Ludwig,et al. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer , 1993, Cancer.
[34] J. Mendelsohn,et al. Crosstalk between epidermal growth factor receptor and P-glycoprotein in actinomycin D-resistant Chinese hamster lung cells. , 1993, Biochemical pharmacology.
[35] J. Peto,et al. Asymptotically Efficient Rank Invariant Test Procedures , 1972 .
[36] B. Spengler,et al. Epidermal growth factor receptor is increased in multidrug-resistant Chinese hamster and mouse tumor cells. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[37] R. Labianca,et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer , 1998, The Lancet.
[38] R. James,et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial , 2000, The Lancet.
[39] J. Berlin,et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.